Biopharmaceutical company developing therapies for neurodegenerative diseases.
Vigil Neuroscience, Inc. is a dynamic clinical-stage biotechnology company dedicated to pioneering treatments for both rare and prevalent neurodegenerative diseases. The company's innovative approach focuses on restoring the vigilance of microglia, the crucial sentinel immune cells of the brain, using advanced neuroscience drug development tools.
Central to Vigil Neuroscience's mission is the development of precision-based therapies aimed at significantly enhancing the quality of life for patients and their families. Leading its pipeline is VGL101, a human momnoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2). Currently undergoing a Phase 2 proof-of-concept trial, VGL101 targets adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and debilitating neurodegenerative disorder.
In parallel, Vigil Neuroscience is addvancing an IND-enabling program centered on a novel small molecule TREM2 agonist. This initiative seeks to address common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease within genetically defined subpopulations. This dual-pronged strategy underscores the company's commitment to developing transformative therapies that address critical unmet medical needs across diverse patient populations.
Established in 2020 and headquartered in Cambridge, Massachusetts, Vigil Neuroscience is strategically positioned at the nexus of biotechnological innovation. The company's robust research efforts and strategic partnerships propel its vision of advancing groundbreaking treatments that harness the potential of neuroimmune modulation to combat neurodegenerative diseases effectively.